Stifel Reiterates Buy Rating on Atara Biotherapeutics (ATRA) with $20 PT, Sees Huge Market Potential for ATA188 on Positive Trial Outcome but Warns of Low Probability of Success
Tweet Send to a Friend
Stifel analyst Benjamin Burnett reiterated a Buy rating and $20.00 price target on Atara Biotherapeutics (NASDAQ: ATRA), following the company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
